UK Study Finds Pfizer/Bristol Myers Clotting Drug Does Not Help COVID-19 Patients

Vandana Singh
1 min read
6
In this article:

  • According to a U.K. trial, Eliquis (apixaban), widely prescribed for COVID-19, did not help patients recovering from moderate and severe COVID.

  • The drug used after discharge from the hospital does not lessen the chances for COVID-19 patients of readmission or improve survival.

  • The results were shared with the Financial Times.

  • Eliquis is indicated to reduce the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat.

  • Related: National Institutes of Health's Long COVID Initiative To Assess Pfizer's Antiviral Pill As Potential Treatment.

  • Apixaban is jointly commercialized by Pfizer Inc (NYSE: PFE) and Bristol Myers Squibb Co (NYSE: BMY).

  • Researchers also found that a small number of cases caused serious harm.

  • Around 29.1% of people given the drug ended up back in the hospital or died, compared with 30.8% receiving standard care.

  • The 402-subject study showed no benefit from Apixaban regarding the number of days patients remained alive and out of the hospital 60 days after their initial discharge.

  • The study will continue to test another drug called Atorvastatin, a widely used lipid-lowering drug, or "statin," that acts on other mechanisms of disease that are thought to be important in COVID.

  • Photo Via Company

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories